JP2009515927A5 - - Google Patents

Download PDF

Info

Publication number
JP2009515927A5
JP2009515927A5 JP2008540580A JP2008540580A JP2009515927A5 JP 2009515927 A5 JP2009515927 A5 JP 2009515927A5 JP 2008540580 A JP2008540580 A JP 2008540580A JP 2008540580 A JP2008540580 A JP 2008540580A JP 2009515927 A5 JP2009515927 A5 JP 2009515927A5
Authority
JP
Japan
Prior art keywords
asymptomatic
latent
heart failure
use according
pde iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008540580A
Other languages
English (en)
Japanese (ja)
Other versions
JP5312034B2 (ja
JP2009515927A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2006/068231 external-priority patent/WO2007054514A2/en
Publication of JP2009515927A publication Critical patent/JP2009515927A/ja
Publication of JP2009515927A5 publication Critical patent/JP2009515927A5/ja
Application granted granted Critical
Publication of JP5312034B2 publication Critical patent/JP5312034B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008540580A 2005-11-14 2006-11-08 無症候性(潜在性)心不全の治療のためのpdeiii阻害剤の使用 Active JP5312034B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05110689 2005-11-14
EP05110689.6 2005-11-14
PCT/EP2006/068231 WO2007054514A2 (en) 2005-11-14 2006-11-08 Use of pde iii inhibitors or calcium sensitizers for the treatment of asymptomatic (occult) heart failure

Publications (3)

Publication Number Publication Date
JP2009515927A JP2009515927A (ja) 2009-04-16
JP2009515927A5 true JP2009515927A5 (enExample) 2010-01-07
JP5312034B2 JP5312034B2 (ja) 2013-10-09

Family

ID=37744668

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008540580A Active JP5312034B2 (ja) 2005-11-14 2006-11-08 無症候性(潜在性)心不全の治療のためのpdeiii阻害剤の使用

Country Status (13)

Country Link
US (2) US20070112010A1 (enExample)
EP (2) EP1951227B1 (enExample)
JP (1) JP5312034B2 (enExample)
CN (2) CN102784394A (enExample)
AR (1) AR056800A1 (enExample)
AU (1) AU2006310997B2 (enExample)
CA (1) CA2629367C (enExample)
DK (1) DK1951227T3 (enExample)
ES (1) ES2631879T3 (enExample)
HU (1) HUE033546T2 (enExample)
PL (1) PL1951227T3 (enExample)
TW (1) TW200735874A (enExample)
WO (1) WO2007054514A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
FI20040674A0 (fi) 2004-05-12 2004-05-12 Orion Corp Menetelmä tromboembolisten sairauksien estoon
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
EP2279009A4 (en) * 2008-05-05 2011-09-21 Univ Rochester METHOD AND COMPOSITIONS FOR TREATING OR PREVENTING PATHOLOGICAL CARDIAL REMODELING AND HEART FAILURE
WO2010060874A1 (en) 2008-11-25 2010-06-03 Boehringer Ingelheim Vetmedica Gmbh Phosphodiesterase type iii (pde iii) inhibitors or ca2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy
NL1037569C2 (en) * 2009-12-18 2011-06-21 Eurovet Animal Health B V Crystalline pimobendan, process for the preparation thereof, pharmaceutical composition and use.
US10398705B2 (en) 2012-03-15 2019-09-03 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
AU2014292086B2 (en) 2013-07-19 2019-08-08 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
MX375936B (es) 2013-12-04 2025-03-07 Boehringer Ingelheim Vetmedica Gmbh Composiciones farmaceuticas mejoradas de pimobendan.
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
PT3439660T (pt) * 2016-06-01 2024-07-18 Boehringer Ingelheim Vetmedica Gmbh Utilização de pimobendan para a redução do tamanho do coração e o retardamento do início de sintomas clínicos em doentes com insuficiência cardíaca assintomática devido a doença da válvula mitral
WO2022073954A1 (en) 2020-10-08 2022-04-14 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan in the anaesthesia of non-human mammals
KR20250151545A (ko) 2023-03-10 2025-10-21 조에티스 서비시즈 엘엘씨 포스포다이에스터레이스 3(pde3) 억제제
AU2024276892A1 (en) 2023-05-24 2025-10-16 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8101067A1 (es) 1978-08-25 1980-12-01 Thomae Gmbh Dr K Procedimiento para la preparacion de nuevos bencimidazoles sustituidos en posicion 5 o 6 con un anillo de piridazinona
GB8400863D0 (en) * 1984-01-13 1984-02-15 Smith Kline French Lab Chemical compounds
DE3677316D1 (de) * 1985-10-17 1991-03-07 Smith Kline French Lab 4(4-oxo-1,4-dihydropyridin-1-yl)phenyl-derivate.
US4868182A (en) 1986-11-05 1989-09-19 Merrell Dow Pharmaceuticals Inc. Enhancement of prazosin
DE3804490A1 (de) * 1988-02-12 1989-08-24 Heumann Pharma Gmbh & Co Substituierte 6-phenyldihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB8824458D0 (en) 1988-10-19 1988-11-23 Orion Yhtymae Oy Substituted pyridazinones
GB8903130D0 (en) 1989-02-11 1989-03-30 Orion Yhtymae Oy Substituted pyridazinones
GB2251615B (en) 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
DE60237696D1 (de) * 2001-08-01 2010-10-28 Univ Utah Am n-terminus trunkierte isoformen von zyklischen phosphodiesterasen pde3a
EP1579862A1 (en) * 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure

Similar Documents

Publication Publication Date Title
US9901568B2 (en) Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound
JP2022180461A5 (enExample)
JP2010536849A5 (enExample)
SI2529622T1 (en) Inhibitors of bruton's tyrosine kinase
ECSP066807A (es) Formulaciones galénicas de compuestos orgánicos
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
JP2011502997A5 (enExample)
JP2011522816A5 (enExample)
JP2005508371A5 (enExample)
NZ584686A (en) Compositions of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate(S)-3'-methyl-2' -(pentanoyl{ 2 -(tetrazol-5-ylate)biphenyl-4'-ylmethyl} amino)butyrate]hemipentahydrate
HRP20240317T1 (hr) Liječenje hepatičke encefalopatije uporabom rifaksimina
JP2014521658A5 (enExample)
JP2008543936A5 (enExample)
JP2018527305A5 (enExample)
JP2014521641A5 (enExample)
JP2008516004A5 (enExample)
JP2015505295A5 (enExample)
JP2011510922A5 (enExample)
JP2009518415A5 (enExample)
JP2017514858A5 (enExample)
JP2009513512A (ja) メロキシカムを含む組成物
JP2003508467A5 (enExample)
WO2007054514A3 (en) Use of pde iii inhibitors or calcium sensitizers for the treatment of asymptomatic (occult) heart failure
JP2008515980A5 (enExample)
RU2007119067A (ru) Средство для лечения синдрома раздраженного кишечника с преобладанием диареи